Purple Biotech Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Purple Biotech Ltd. on October 2, 2024, for the month of October 2024. The Company is a foreign private issuer headquartered in Rehovot, Israel, and lists its American Depositary Shares (ADSs) on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of regulatory compliance rather than a financial statement.
Material Changes
The primary material event reported is the resolution of a listing deficiency. On October 1, 2024, the Company received confirmation from the Nasdaq Listing Qualifications Department that it regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement. The Company successfully maintained a closing bid price of at least $1.00 per ADS for 10 consecutive business days, concluding on September 30, 2024. The matter is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No new risks or contingencies were disclosed in this specific report, other than the historical risk of non-compliance which has been resolved.
Key Facts for Investor Verification
- The Company has regained compliance with Nasdaq's minimum bid price requirement ($1.00 per ADS).
- The compliance period was achieved by September 30, 2024.
- The Nasdaq Listing Qualifications Department has officially closed the compliance matter.
- No financial performance data is included in this filing.